Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance

FXR is a molecular target for the effects of vertical sleeve gastrectomy

(2014) Karen K. Ryan et al.   NATURE

Systemic bile acid sensing by G protein-coupled bile acid receptor 1 (GPBAR1) promotes PYY and GLP-1 release

(2013) C Ullmer et al.   BRITISH JOURNAL OF PHARMACOLOGY

Diet1 Functions in the FGF15/19 Enterohepatic Signaling Axis to Modulate Bile Acid and Lipid Levels

(2013) Laurent Vergnes et al.   Cell Metabolism

Efficacy and Safety of the Farnesoid X Receptor Agonist Obeticholic Acid in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease

(2013) Sunder Mudaliar et al.   GASTROENTEROLOGY

An inhibitor of the protein kinases TBK1 and IKK-ɛ improves obesity-related metabolic dysfunctions in mice

(2013) Shannon M Reilly et al.   NATURE MEDICINE

STAR: ultrafast universal RNA-seq aligner

(2012) Alexander Dobin et al.   BIOINFORMATICS

FGF21 regulates PGC-1  and browning of white adipose tissues in adaptive thermogenesis

(2012) f. M. Fisher et al.   GENES & DEVELOPMENT

G protein–coupled receptor 21 deletion improves insulin sensitivity in diet-induced obese mice

(2012) Olivia Osborn et al.   JOURNAL OF CLINICAL INVESTIGATION

Differential analysis of gene regulation at transcript resolution with RNA-seq

(2012) Cole Trapnell et al.   NATURE BIOTECHNOLOGY

Identification of novel transcripts in annotated genomes using RNA-Seq

(2011) A. Roberts et al.   BIOINFORMATICS

Farnesoid X Receptor Deficiency Improves Glucose Homeostasis in Mouse Models of Obesity

(2011) J. Prawitt et al.   DIABETES

Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease

(2011) R. M. Gadaleta et al.   GUT

Lowering Bile Acid Pool Size with a Synthetic Farnesoid X Receptor (FXR) Agonist Induces Obesity and Diabetes through Reduced Energy Expenditure

(2011) Mitsuhiro Watanabe et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

FGF19 Regulates Cell Proliferation, Glucose and Bile Acid Metabolism via FGFR4-Dependent and Independent Pathways

(2011) Ai-Luen Wu et al.   PLoS One

Human Fatty Liver Disease: Old Questions and New Insights

(2011) J. C. Cohen et al.   SCIENCE

Intestinal FXR-mediated FGF15 production contributes to diurnal control of hepatic bile acid synthesis in mice

(2010) Johanna H M Stroeve et al.   LABORATORY INVESTIGATION

CRTC3 links catecholamine signalling to energy balance

(2010) Youngsup Song et al.   NATURE

FXR Acetylation Is Normally Dynamically Regulated by p300 and SIRT1 but Constitutively Elevated in Metabolic Disease States

(2009) Jongsook Kim Kemper et al.   Cell Metabolism

Genome-wide tissue-specific farnesoid X receptor binding in mouse liver and intestine

(2009) Ann M. Thomas et al.   HEPATOLOGY

Fibroblast Growth Factor-19, a Novel Factor That Inhibits Hepatic Fatty Acid Synthesis

(2009) Sushant Bhatnagar et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Bile acids activate fibroblast growth factor 19 signaling in human hepatocytes to inhibit cholesterol 7α-hydroxylase gene expression

(2008) Kwang-Hoon Song et al.   HEPATOLOGY

The p300 Acetylase Is Critical for Ligand-activated Farnesoid X Receptor (FXR) Induction of SHP

(2008) Sungsoon Fang et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Liver X Receptor   Is a Transcriptional Repressor of the Uncoupling Protein 1 Gene and the Brown Fat Phenotype

(2008) H. Wang et al.   MOLECULAR AND CELLULAR BIOLOGY